From the 67th annual scientific sessions of the American Diabetes Association: Exenatide associated with sustained blood glucose control, weight loss after 3 years of treatment
An open-label extension study of exenatide demonstrated sustained blood glucose control and weight loss in patients with type 2 diabetes.
Key Points
An open-label extension study of exenatide demonstrated sustained blood glucose control and weight loss in patients with type 2 diabetes, said John Buse, MD, chief, Division of General Medicine and Clinical Epidemiology, University of North Carolina, Chapel Hill.
Previously announced 2-year data collected during the extension phase of the trial demonstrated a –1.1% decrease in HbA1c levels and a –4.7-kg decline in body weight from baseline among patients randomized to exenatide. Both postprandial glucose and fasting plasma glucose levels were reduced with use of exenatide.
"Eighty-four percent of 3-year completers experienced weight reduction," Dr Buse said. "Sixty-eight percent both lost weight and had a reduction in [Hb]A1c."
A subgroup analysis demonstrated a 17% improvement in homeostasis model assessment-B (HOMA-B), a surrogate of beta-cell function, from baseline to 3 years, Dr. Buse said.
Medicare’s Drug Price Negotiations Could Impact Physician Reimbursement
September 19th 2024When CMS begins negotiations for physician-administered drugs under the Inflation Reduction Act, providers, including those whose services are covered by commercial insurance, could see lowered reimbursement.
Read More
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
Diabetes Management & Telehealth with Leslie Kolb
June 11th 2020Association of Diabetes Care and Education Specialists, chief science and practice officer, Leslie Kolb chats with MHE Associate Editor Briana Contreras in MHE's newest podcast Tuning into the C-Suite about diabetes management and how it's affected by the use of telehealth, especially during the current and trying times of the COVID-19 pandemic.
Listen
